You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
NameSalmon Calcitonin
Accession NumberDB00017  (BIOD00025, BTD00025)
GroupsApproved, Investigational

Synthetic peptide, 32 residues long formulated as a nasal spray.

Protein structureDb00017
Protein chemical formulaC145H240N44O48S2
Protein average weight3431.8530
>DB00017 sequence
Download FASTA Format
CalcimarNot AvailableNot Available
Calcitonin (Salmon Synthetic)Not AvailableNot Available
Calcitonin 1 precursorNot AvailableNot Available
Calcitonin SalmonNot AvailableNot Available
Calcitonin-salmonNot AvailableNot Available
Calcitonin, salmonNot AvailableNot Available
CibacalcinNot AvailableNot Available
ForticalNot AvailableNot Available
MiacalcinNot AvailableNot Available
Salmon calcitoninNot AvailableNot Available
SalmotoninNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Miacalcininjection, solution200 [iU]/mLintramuscular; subcutaneousNovartis Pharmaceuticals Corporation1986-07-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Miacalcinspray, metered200 [iU]nasalNovartis Pharmaceuticals Corporation1995-08-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Forticalspray, metered2200 [iU]/mLnasalUpsher Smith Laboratories, Inc.2005-08-12Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Forticalspray, metered2200 [iU]/mLnasalPhysicians Total Care, Inc.2005-12-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcitonin Salmonspray, metered200 [iU]nasalApotex Corp.2008-12-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
CalcimarNot Available
Brand mixturesNot Available
SaltsNot Available
CAS number47931-85-1
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
IndicationUsed in the treatment of symptomatic Paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments. In addition, it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified. It can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. Calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves. Also for the treatment of post-menopausal osteoporosis in women more than 5 years post-menopause.
PharmacodynamicsCalcitonin inhibits bone resorption by osteoclasts (bone remodeling cells) and promotes bone formation by osteoblasts. This leads to a net increase in bone mass and a reduction in plasma calcium levels. It also promotes the renal excretion of ions such as calcium, phosphate, sodium, magnesium, and potassium by decreasing tubular reabsorption. In consequence, there is an increase in the jejunal secretion of water, sodium, potassium, and chloride.
Mechanism of actionCalcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
AbsorptionSalmon calcitonin is rapidly absorbed and eliminated. Bioavailability following subcutaneous and intramuscular injection in humans is high and similar for the two routes of administration (71% and 66%, respectively). Via the nasal route, the bioavailability varies between 3 to 5% relative to IM.
Volume of distribution

0.15 to 0.3 L/kg

Protein binding30 to 40%

Salmon calcitonin is primarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule. It is also metabolized in the blood and the peripheral tissue.

Route of eliminationUrine. Studies with injectable calcitonin show increases in the excretion of filtered phosphate, calcium, and sodium by decreasing their tubular reabsorption in the kidney.
Half lifeHalf-life elimination (terminal): I.M. 58 minutes; SubQ 59 to 64 minutes; Nasal: ~18 to 23 minutes
ClearanceNot Available
ToxicitySalmon calcitonin was shown to inhibit lactation in animals and is not recommend in nursing mothers. While research in animals have shown a decrease in fetal weight, no studies have yet shown similar results in humans. It is recommended however to proceed carefully when administering salmon calcitonin to pregnant women and consider if the benefits outweigh the risks. Because of its protein nature, salmon calcitonin may provoke an allergy reaction (bronchospams and swelling of the tongue/throat) that can turn into a full-blown anaphylactic response. The manufacturer also reports an increase in the risk of malignancies from oral route (0.7%) to intranasal route (2.4%) compared to placebo. The same may apply to IV, IM and SC routes since the systemic exposure is higher in those cases. Nausea is noticeable in some patients but tends to decrease with continued administration. Rhinitis, headaches and back pain have also been reported among others.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
  • Sanofi aventis us llc
  • Astrazeneca lp
  • Novartis pharmaceuticals corp
  • Apotex inc
  • Par pharmaceutical inc
  • Upsher smith laboratories inc
Dosage forms
Injection, solutionintramuscular; subcutaneous200 [iU]/mL
Spray, meterednasal200 [iU]
Spray, meterednasal2200 [iU]/mL
Unit descriptionCostUnit
Miacalcin 200 unit/act Solution 3.7ml Bottle139.39USD bottle
Calcitonin (Salmon) 200 unit/act Solution 3.7ml Bottle123.28USD bottle
Miacalcin For Inj, 2 unit = 1 Box 2ml Vial63.59USD vial
Miacalcin 200 unit nasal spray44.68USD ml
Calcitonin-salmon 200 unit sp39.51USD ml
Fortical 200 unit nasal spray34.3USD ml
Miacalcin 200 unit/ml vial30.73USD ml
Calcimar 200 iu/ml29.94USD ml
Caltine 100 (100 Iu/Ml) 100 iu/ml8.81USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
CountryPatent NumberApprovedExpires (estimated)
United States57335691995-03-312015-03-31
United States64403922001-02-022021-02-02
Experimental Properties
hydrophobicity-0.537Not Available
isoelectric point8.86Not Available
Synthesis Reference

Marcos C. Poblet, Berta P. Obiols, Gemma J. Farres, “Procedure for preparing salmon calcitonin.” U.S. Patent US5527881, issued October, 1991.

General Reference
  1. Sanofi-Aventis Canada Inc. Calcimar Solution. Laval, Quebec: N.p., 2014.
    #Lexicomp. Calcitonin. N.p., 2014. Web. 11 Nov. 2014.
External Links
ATC CodesNot Available
AHFS Codes
  • 68:24.00
PDB Entries
FDA labelNot Available
MSDSNot Available
Drug InteractionsNot Available
Food InteractionsNot Available


1. Calcitonin receptor

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: agonist


Name UniProt ID Details
Calcitonin receptor P30988 Details


  1. Bouizar Z, Fouchereau-Peron M, Taboulet J, Moukhtar MS, Milhaud G: Purification and characterization of calcitonin receptors in rat kidney membranes by covalent cross-linking techniques. Eur J Biochem. 1986 Feb 17;155(1):141-7. Pubmed
  2. Stroop SD, Moore EE: Intracellular calcium increases mediated by a recombinant human calcitonin receptor. J Bone Miner Res. 1995 Apr;10(4):524-32. Pubmed
  3. Sarkar A, Dickerson IM: Cloning, characterization, and expression of a calcitonin receptor from guinea pig brain. J Neurochem. 1997 Aug;69(2):455-64. Pubmed
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 07, 2015 13:08